Serum Golgi protein 73 levels and liver pathological grading in cases of chronic hepatitis B

Xu,Zhengju; Pan,Xingnan; Wei,Kaipeng; Ding,Hongbing; Wei,Meijuan; Yang,Huanwen; Liu,Qian

doi:10.3892/mmr.2014.3114

Serum Golgi protein 73 levels and liver pathological grading in cases of chronic hepatitis B

Authors:
- Zhengju Xu
- Xingnan Pan
- Kaipeng Wei
- Hongbing Ding
- Meijuan Wei
- Huanwen Yang
- Qian Liu
View Affiliations

Affiliations: Clinical Liver Center, The 180th Hospital of the People's Liberation Army, Quanzhou, Fujian 362000, P.R. China, Central Laboratory of Clinical Hepatology, The 180th Hospital of the People's Liberation Army, Quanzhou, Fujian 362000, P.R. China, Liver Center Clinical Pathology, The 180th Hospital of the People's Liberation Army, Quanzhou, Fujian 362000, P.R. China
Published online on: December 18, 2014 https://doi.org/10.3892/mmr.2014.3114
Pages: 2644-2652
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was designed to assess the correlation between serum Golgi protein 73 (GP73) and liver pathological grading and staging in patients with chronic hepatitis B (CHB). Two hundred and fifty‑three patients with chronic hepatitis B virus (HBV) infections were enrolled in the present study. All patients received a serum GP73 test, and 91 CHB patients underwent liver biopsy. GP73 expression in liver tissue was assessed by immunohistochemical analysis. The results indicated that serum GP73 levels were positively correlated with disease progression in patients with chronic HBV infection (r=0.677). There was no significant difference in serum GP73 levels between hepatitis B e antigen‑positive and ‑negative patients (P>0.05). There were also no significant differences in serum GP73 levels among specimens with varying HBV DNA contents (P>0.05). Serum GP73 levels were positively correlated with increased liver pathological grading (r=0.737) and staging (r=0.692), and immunohistochemical analysis indicated that GP73 protein expression increased concurrently with liver pathological grading and staging. In conclusion, serum GP73 was found to be correlated with liver pathological grading and staging in patients with CHB, and may be an effective indicator for the evaluation of disease progression. However, serum GP73 levels were not associated with HBV replication.

View Figures

View References

1	European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 57:167–185. 2012.PubMed/NCBI
2	World Health Organization. Hepatitis B Factsheet 204. http://www.who.int/mediacentre/factsheets/fs204/en/index.html. Accessed 2013
3	Zhou YH, Wu C and Zhuang H: Vaccination against hepatitis B: the Chinese experience. Chin Med J (Engl). 122:98–102. 2009.
4	Rotman Y, Brown TA and Hoofnagle JH: Evaluation of the patient with hepatitis B. Hepatology. 49(5 Suppl): S22–S27. 2009. View Article : Google Scholar : PubMed/NCBI
5	Kladney RD, Bulla GA, Guo L, Mason AL, et al: GP73, a novel Golgi-localized protein upregulated by viral infection. Gene. 249:53–65. 2000. View Article : Google Scholar : PubMed/NCBI
6	Riener MO, Stenner F, Liewen H, Soll C, et al: Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology. 49:1602–1609. 2009. View Article : Google Scholar : PubMed/NCBI
7	Kladney RD, Cui X, Bulla GA, Brunt EM, et al: Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 35:1431–1440. 2002. View Article : Google Scholar : PubMed/NCBI
8	Sun Y, Yang H, Mao Y, Xu H, et al: Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J Gastroenterol Hepatol. 26:1207–1212. 2011. View Article : Google Scholar : PubMed/NCBI
9	Maitra A and Thuluvath PJ: GP73 and liver disease: a (Golgi) complex enigma. Am J Gastroenterol. 99:1096–1098. 2004. View Article : Google Scholar : PubMed/NCBI
10	Wright LM, Yong S, Picken MM, Rockey D, et al: Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clinical Exp Pathol. 2:34–47. 2009.
11	Iftikhar R, Kladney RD, Havlioglu N, Schmitt-Graff A, et al: Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol. 99:1087–1095. 2004. View Article : Google Scholar : PubMed/NCBI
12	Sterling RK, Jeffers L, Gordon F, Sherman M, et al: Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol. 102:2196–2205. 2007. View Article : Google Scholar : PubMed/NCBI
13	Chen WL, Peng T, Chen XP, et al: Clinical significance of serum GP73 test in diagnosis of liver diseases. Chin J Lab Med. 33:333–336. 2010.(In Chinese).
14	Chinese Society of Infectious Diseases and Parasitology and Chinese Society of Hepatology of Chinese Medical Association. The programme of prevention and cure for viral hepatitis. Chin J Hepatol. 8:324–329. 2000.(In Chinese).
15	Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, et al: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:646–649. 1973. View Article : Google Scholar : PubMed/NCBI
16	Sarin SK, Kumar A, Almeida JA, Chawla YK, et al: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 3:269–282. 2009. View Article : Google Scholar : PubMed/NCBI
17	Scheuer PJ: Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 13:372–374. 1991. View Article : Google Scholar : PubMed/NCBI
18	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi. 19:13–24. 2011.(In Chinese).
19	Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, et al: Liver biopsy. Hepatology. 49:1017–1044. 2009. View Article : Google Scholar : PubMed/NCBI
20	Mani H and Kleiner DE: Liver biopsy findings in chronic hepatitis B. Hepatology. 49(5 Suppl): S61–S71. 2009. View Article : Google Scholar : PubMed/NCBI
21	Bachert C, Fimmel C and Linstedt AD: Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic. 8:1415–1423. 2007. View Article : Google Scholar : PubMed/NCBI
22	Fimmel CJ and Wright L: Golgi protein 73 as a biomarker of hepatocellular cancer: development of a quantitative serum assay and expression studies in hepatic and extrahepatic malignancies. Hepatology. 49:1421–1423. 2009. View Article : Google Scholar : PubMed/NCBI
23	Mao Y, Yang H, Xu H, Lu X, et al: Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 59:1687–1693. 2010. View Article : Google Scholar : PubMed/NCBI
24	Marrero JA, Romano PR, Nikolaeva O, Steel L, et al: GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 43:1007–1012. 2005. View Article : Google Scholar : PubMed/NCBI
25	Norton PA, Comunale MA, Krakover J, Rodemich L, et al: N-linked glycosylation of the liver cancer biomarker GP73. J Cellular Biochem. 104:136–149. 2008. View Article : Google Scholar
26	Schwegler EE, Cazares L, Steel LF, Adam BL, et al: SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology. 41:634–642. 2005. View Article : Google Scholar : PubMed/NCBI
27	Shi Y, Chen J, Li L, Sun Z, et al: A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Can Res Treat. 10:287–294. 2011.
28	Yamamoto K, Imamura H, Matsuyama Y, Kume Y, et al: AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 45:1272–1282. 2010. View Article : Google Scholar : PubMed/NCBI
29	Qiao Y, Chen J, Li X, Wei H, et al: Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection. Clin Biochem. 47:216–222. 2014. View Article : Google Scholar : PubMed/NCBI
30	Tian L, Wang Y, Xu D, Gui J, et al: Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. International journal of cancer. J Int Du Cancer. 129:1923–1931. 2011. View Article : Google Scholar
31	Wright LM, Huster D, Lutsenko S, Wrba F, et al: Hepatocyte GP73 expression in Wilson disease. J Hepatol. 51:557–564. 2009. View Article : Google Scholar : PubMed/NCBI
32	Liu X, Wan X, Li Z, Lin C, et al: Golgi protein 73 (GP73), a useful serum marker in liver diseases. Clin Chem Lab Med. 49:1311–1316. 2011. View Article : Google Scholar : PubMed/NCBI
33	Cao Q, Mak KM and Lieber CS: Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells. J Hepatol. 46:124–133. 2007. View Article : Google Scholar
34	Hoofnagle JH: Reactivation of hepatitis B. Hepatology. 49(5 Suppl): S156–S165. 2009. View Article : Google Scholar : PubMed/NCBI
35	Block TM, Comunale MA, Lowman M, Steel LF, et al: Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA. 102:779–784. 2005. View Article : Google Scholar : PubMed/NCBI